Peak Bio (PKBO) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 02, 2021
Document Information [Line Items]
Document Type	10-Q
Entity Central Index Key	0001834645
Document Period End Date	Jun. 30, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39951
Entity Registrant Name	Ignyte Acquisition Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2448157
Entity Address, Address Line One	640 Fifth Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	409-2000
Entity Information, Former Legal or Registered Name	N/A
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		7,287,500
Common Stock and Redeemable Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one share of common stock and one-half of one redeemable warrant
Trading Symbol	IGNYU
Name of Exchange on which Security is Registered	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	IGNY
Name of Exchange on which Security is Registered	NASDAQ
Redeemable Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share
Trading Symbol	IGNYW
Name of Exchange on which Security is Registered	NASDAQ

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Assets
Cash	$ 550,470	$ 25,425
Prepaid expense and other current assets	181,923
Total current assets	732,393	25,425
Deferred offering costs		81,575
Cash and securities held in Trust Account	57,504,345
Total Assets	58,236,738	107,000
Current liabilities:
Accrued expenses	12,656
Due to related party	51,953	310
Promissory note - related party		80,000
Total current liabilities	64,609	80,310
Warrant liabilities	1,875,000
Total liabilities	1,939,609	80,310
Commitments and Contingencies
Common stock subject to possible redemption, 5,129,712 shares at redemption value	51,297,120
Stockholders' Equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value; 50,000,000 shares authorized; 2,157,788 shares and 0 shares issued and outstanding (excluding 5,129,712 shares and 0 shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively	216	154
Additional paid-in capital	4,730,179	26,846
Retained earnings (Accumulated deficit)	269,614	(310)
Total stockholders' equity	5,000,009	26,690
Total Liabilities and Stockholders' Equity	$ 58,236,738	$ 107,000

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Feb. 01, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Number of shares subject to redemption	5,129,712	4,367,012	0
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized	1,000,000		1,000,000
Preferred Stock, Shares Issued	0		0
Preferred Stock, Shares Outstanding	0		0
Common Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001
Common Stock, Shares Authorized	50,000,000		50,000,000
Common Stock, Shares, Issued	2,157,788		2,157,788
Common Stock, Shares, Outstanding	0		0

UNAUDITED CONDENSED STATEMENTS

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Income Statement [Abstract]
Formation and operating costs	$ 110,980	$ 309,421
Loss from operations	(110,980)	(309,421)
Other income
Change in fair value of warrants	725,000	575,000
Trust interest income	2,087	4,345
Total other income	727,087	579,345
Net income	$ 616,107	$ 269,924
Basic and diluted weighted average shares outstanding, common stock subject to redemption	5,068,102	4,183,046
Basic and diluted net loss per share	$ 0	$ 0
Basic and diluted weighted average shares outstanding, common stock	2,219,398	2,053,694
Basic and diluted net loss per share	$ 0.28	$ 0.13

UNAUDITED CONDENSED STATEMENT_2

UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2020	$ 154	$ 26,846	$ (310)	$ 26,690
Balance (in Shares) at Dec. 31, 2020	1,537,500
Sale of 5,000,000 and 750,000 Units on February 1, 2021 and February 2, 2021 through IPO and over-allotment, respectively	$ 575	57,499,425		57,500,000
Sale of 5,000,000 and 750,000 Units on February 1, 2021 and February 2, 2021 through IPO and over-allotment, respectively (in Shares)	5,750,000
Sale of 2,350,000 and 150,000 Placement Warrants on February 1, 2021 and February 2, 2021, respectively, net of fair value of warrant liabilities		50,000		50,000
Underwriting fee		(1,150,000)		(1,150,000)
Other offering expenses		(399,485)		(399,485)
Change in value of common stock subject to possible redemption	$ (507)	(50,680,513)		(50,681,020)
Change in value of common stock subject to possible redemption (in Shares)	(5,068,201)
Net income (loss)			(346,183)	(346,183)
Balance at Mar. 31, 2021	$ 222	5,346,273	(346,493)	5,000,002
Balance (in Shares) at Mar. 31, 2021	2,219,398
Balance at Dec. 31, 2020	$ 154	26,846	(310)	26,690
Balance (in Shares) at Dec. 31, 2020	1,537,500
Other offering expenses				(399,485)
Net income (loss)				269,924
Balance at Jun. 30, 2021	$ 216	4,730,179	269,614	5,000,009
Balance (in Shares) at Jun. 30, 2021	2,157,788
Balance at Mar. 31, 2021	$ 222	5,346,273	(346,493)	5,000,002
Balance (in Shares) at Mar. 31, 2021	2,219,398
Change in value of common stock subject to possible redemption	$ (6)	(616,094)		(616,100)
Change in value of common stock subject to possible redemption (in Shares)	(61,610)
Net income (loss)			616,107	616,107
Balance at Jun. 30, 2021	$ 216	$ 4,730,179	$ 269,614	$ 5,000,009
Balance (in Shares) at Jun. 30, 2021	2,157,788

UNAUDITED CONDENSED STATEMENT_3

UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - shares	Feb. 02, 2021	Feb. 01, 2021
Through IPO and over-allotment [Member]
Number of sale of units	750,000	5,000,000
Placement Warrants [Member]
Number of sale of units	150,000	2,350,000

UNAUDITED CONDENSED STATEMENT O

UNAUDITED CONDENSED STATEMENT OF CASH FLOWS	6 Months Ended
	Jun. 30, 2021USD ($)
Cash flows from Operating Activities:
Net income	$ 269,924
Adjustments to reconcile net income to net cash used in operating activities:
Increase in fair value of warrants	(575,000)
Interest earned on marketable securities held in Trust Account	(4,345)
Changes in current assets and current liabilities:
Prepaid expenses	(181,923)
Accrued offering costs and expenses	12,656
Due to related party	51,643
Net cash used in operating activities	(427,045)
Cash Flows from Investing Activities:
Purchase of investment held in Trust Account	(57,500,000)
Net cash used in investing activities	(57,500,000)
Cash flows from Financing Activities:
Proceeds from Initial Public Offering, net of underwriters' fees	56,350,000
Proceeds from private placement	2,500,000
Repayment of promissory note to related party	(80,000)
Payments of offering costs	(317,910)
Net cash provided by financing activities	58,452,090
Net change in cash	525,045
Cash, beginning of the period	25,425
Cash, end of the period	550,470
Supplemental disclosure of noncash investing and financing activities:
Initial value of Common stock subject to possible redemption, as revised	51,023,118
Change in value of Common stock subject to possible redemption	274,002
Initial fair value of warrant liabilities	$ 2,450,000

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Note 1 — Organization and Business Operations Organization and General Ignyte Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated as a Delaware corporation on August 6, 2020. The Company was incorporated for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses (the “Business Combination”). The Company has selected December 31 as its fiscal year end. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of June 30, 2021, the Company had not commenced any operations. All activity for the period from August 6, 2020 (inception) through June 30, 2021 relates to the Company's formation and the initial public offering (“IPO”), which is described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO. The Company's sponsor is Ignyte Sponsor LLC (the “Sponsor”), a Delaware limited liability company (the “Sponsor”). Financing The registration statement for the Company's IPO was declared effective on January 27, 2021 (the “Effective Date”). On February 1, 2021, the Company consummated the IPO of 5,000,000 units (the “Units” and, with respect to the shares of common stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $50,000,000, which is discussed in Note 4. Simultaneously with the closing of the IPO, the Company consummated the sale of 2,350,000 Private Placement Warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to the Sponsor, generating total gross proceeds of $2,350,000. On February 2, 2021, the underwriters purchased an additional 750,000 Units to exercise its over-allotment option in full at a purchase price of $10.00 per Unit, generating gross proceeds of $7,500,000. Simultaneously with the closing of the full exercise of the over-allotment option, the Company completed the private sale of an aggregate of 150,000 Private Placement Warrants to the Sponsor, at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds of $150,000. A total of $7,500,000 was placed in the Trust Account after the payment of $150,000 underwriting discount. Transaction costs amounted to $1,549,485 consisting of $1,150,000 of underwriting discount and $399,485 of other offering costs. In addition, $975,465 of cash was held outside of the Trust Account (as defined below) and is available for working capital purposes. Trust Account Following the closing of the IPO, on February 1, 2021, $50,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was held in a Trust Account (“Trust Account”), and will invest only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay income tax obligations, the proceeds from the IPO will not be released from the Trust Account until the earlier of the completion of a Business Combination or the Company's redemption of 100% of the outstanding Public Shares if it has not completed a Business Combination in the required time period. The proceeds held in the Trust Account may be used as consideration to pay the sellers of a target business with which the Company completes a Business Combination. Any amounts not paid as consideration to the sellers of the target business may be used to finance operations of the target business. 5 Initial Business Combination In connection with any proposed Business Combination, the Company will either (1) seek stockholders approval of the initial Business Combination at a meeting called for such purpose at which stockholders may seek to convert their shares, regardless of whether they vote for or against the proposed Business Combination or don't vote at all, into their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), or (2) provide its stockholders with the opportunity to sell their shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), in each case subject to the limitations described herein. The decision as to whether the Company will seek stockholders approval of a proposed Business Combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company, solely in its discretion, The shares of Common Stock subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. The Company will have 21 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”). However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company but net of taxes payable ( and less up to $50,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining stockholders and the Company's board of directors, liquidate and dissolve, subject (in the case of (ii) and (iii) above) to the Company's obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. The Sponsor, officers and directors have agreed (i) to vote any shares owned by them in favor of any proposed Business Combination, (ii) not to convert any shares in connection with a stockholder vote to approve a proposed initial Business Combination or sell any shares to the Company in a tender offer in connection with a proposed initial Business Combination, (iii) that the founders' shares will not participate in any liquidating distributions from the Company's Trust Account upon winding up if a Business Combination is not consummated. The Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced below $10.00 per share by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company. The agreement entered into by the Sponsor specifically provides for two exceptions to the indemnity it has given: it will have no liability (1) as to any claimed amounts owed to a target business or vendor or other entity who has executed an agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held in the Trust Account, or (2) as to any claims for indemnification by the underwriters of the Proposed Public Offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has it independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Sponsor's only assets are securities of the Company. Therefore, the Company believes it is unlikely that the Sponsor will be able to satisfy its indemnification obligations if it is required to do so. Liquidity and Capital Resources As of June 30, 2021, the Company had $550,470 in its operating bank account, and working capital of $667,784. Prior to the completion of the Initial Public Offering, the Company's liquidity needs had been satisfied through a payment from the Sponsor of $25,000 (see Note 6) for the Founder Shares to cover certain offering costs, the loan under an unsecured promissory note from the Sponsor of $80,000 (see Note 6), and the net proceeds from the consummation of the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Company's Sponsor or an affiliate of the Sponsor or the Company's officers and directors or their affiliates may, but are not obligated to, provide the Company Working Capital Loans (see Note 6). To date, there were no amounts outstanding under any Working Capital Loans. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

Revision of Previously Issued F

Revision of Previously Issued Financial Statements	6 Months Ended
	Jun. 30, 2021
Revision Of Previously Issued Financial Statements
Revision of Previously Issued Financial Statements	Note 2 — Revision of Previously Issued Financial Statements On April 12, 2021, the Staff of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled "Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies ("SPACs")" (the "SEC Statement"). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a Business Combination, which terms are similar to those contained in the warrant agreement, dated as of January 27, 2021, between the Company and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the "Warrant Agreement"). Historically, the warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on the application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity's Own Equity (“ASC 815-40). The views expressed in the SEC Staff Statement were not consistent with the Company's historical interpretation of the specific provisions within its warrant agreement and the Company's application of ASC 815-40 to the warrant agreement. the Company reevaluated the accounting treatment of (i) the 2,875,000 Public Warrants and (ii) the 2,500,000 Private Placement Warrants (See Note 4 and Note 5). Based on this reassessment, management determined that the private warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company Statement of Operations each reporting period. The Company's management and the audit committee of the Company's Board of Directors concluded that it is appropriate to revise the Company's previously issued audited balance sheet as of February 1, 2021 as previously reported in its Form 8-K. The following tables summarize the effect of the restatement on each balance sheet line item as of the date: As Previously Reported Adjustment As Revised Balance Sheet at February 1, 2021 Warrant Liabilities $ - $ 2,303,000 $ 2,303,000 Total Liabilities 426,200 2,303,000 2,729,200 Common stock subject to possible redemption 45,973,118 (2,303,000) 43,670,118 Common stock 194 23 217 Additional paid-in capital 5,004,203 (23) 5,004,180 Accumulated deficit $ (4,396) $ - $ (4,396) Total Stockholders' Equity 5,000,001 - 5,000,001 Number of shares subject to redemption 4,597,312 (230,300) 4,367,012

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 10-K filed by the Company with the SEC. 7 Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020. Marketable Securities Held in Trust Account At June 30, 2021, the assets held in the Trust Account were invested in money market funds. Fair Value Measurements FASB ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC 820”) defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value of the Company’s certain assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet. The fair values of cash, prepaid assets, and accounts payable are estimated to approximate the carrying values as of December 31, 2020 due to the short maturities of such instruments. 8 The Company’s warrant liabilities are based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. See Note 7 for additional information on assets and liabilities measured at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2021 and December 31, 2020, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption rights that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet. Net Income Per Common Share Net income per common share is computed by dividing net income by the weighted average number of common stock outstanding for each of the periods. The calculation of diluted net income per common share does not include warrants since the inclusion of such warrants would be anti-dilutive. The Company's statement of operations includes a presentation of income per share for common stock subject to possible redemption in a manner similar to the two-class method of income per common share. Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common share, basic and diluted, for non-redeemable common stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the founder shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account. For the Three Months Ended For the Six Months Ended June 30, 2021 June 30, 2021 Common stock subject to possible redemption Numerator: net income allocable to common stock subject to possible redemption Interest income on marketable securities held in trust $ 1,862 $ 3,876 Less: interest available to be withdrawn for payment of taxes - - Net income allocable to common stock subject to possible redemption 1,862 3,876 Denominator: Weighted average redeemable common stock Redeemable common stock, basic and diluted 5,068,102 4,183,046 Basic and diluted net income per share, redeemable common stock $ - $ - Non-redeemable common stock Numerator: net income minus redeemable net earnings Net income $ 616,107 $ 269,924 Redeemable net earnings (1,862) (3,876) Non-redeemable net income 614,245 266,048 Denominator: Weighted average non-redeemable basic and diluted weighted average shares outstanding, common stock 2,219,398 2,053,694 Basic and diluted net income per share, common stock $ 0.28 $ 0.13 9 Offering Costs associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to stockholders' equity upon the completion of the IPO. Accordingly, as of February 1, 2021, offering costs in the aggregate of $1,549,485 have been charged to stockholders' equity (consisting of $1,150,000 of underwriting discount and $399,485 of other offering costs). Warrant Liabilities The Company accounts for the Public Warrants and Private Warrants (as defined in Note 4 and 5) collectively (“Warrants”), as either equity or liability-classified instruments based on an assessment of the specific terms of the Warrants and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants meet all of the requirements for equity classification under ASC 815, including whether the Warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and as of each subsequent quarterly period end date while the Warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Private Warrants in accordance with ASC 815-40 under which the Private Warrants do not meet the criteria for equity classification and must be recorded as liabilities. The fair value of the Private Warrants has been estimated using the Monte Carlo simulation model. See Note 7 for further discussion of the pertinent terms of the Warrants used to determine the value of the Private Warrants and Representative’s Warrants. The Company evaluated the Public Warrants in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” and concluded that they met the criteria for equity classification and are required to be recorded as part a component of additional paid-in capital at the time of issuance. Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. 10 ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the ”COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s financial position will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s financial position may be materially adversely affected. Additionally, the Company’s ability to complete an initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an initial Business Combination in a timely manner. The Company’s ability to consummate an initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. The financial statement does not include any adjustments that might result from the outcome of this uncertainty. Recent Accounting Standards Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statement.

Initial Public Offering

Initial Public Offering	6 Months Ended
	Jun. 30, 2021
Initial Public Offering [Abstract]
Initial Public Offering	Note 4 — Initial Public Offering On February 1, 2021, the Company sold 5,000,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of common stock and one-half of one warrant to purchase one share of common stock (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. On February 2, 2021, the Underwriters exercised the over-allotment option in full to purchase 750,000 Units (the “Over-Allotment Units”), generating an aggregate of gross proceeds of $7,500,000, and incurred $150,000 in underwriting fees. Public Warrants Each whole warrant entitles the holder to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable 30 days after the completion of the Company's initial Business Combination. However, no warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to such shares of common stock. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within a specified period following the consummation of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose will mean the average reported last sale price of the shares of common stock for the 5 trading days ending on the trading day prior to the date of exercise. The warrants will expire on the fifth anniversary of the completion of an initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. 11 The Company may call the warrants for redemption (excluding the Private Placement Warrants and any warrants underlying additional units issued to the Sponsor, initial stockholders, officers, directors or their affiliates in payment of Working Capital Loans made to the Company) • in whole and not in part; • at a price of $0.01 per warrant; • at any time after the warrants become exercisable, • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations) for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and • if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants. If the Company calls the warrants for redemption as described above, the Company's management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the shares of common stock for the 5 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. In addition, if (x) the Company issue additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company's board of directors, and in the case of any such issuance to the Sponsor, initial stockholders or their affiliates, without taking into account any founders' shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the consummation of the initial Business Combination (net of redemptions), and (z) the Market Value is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities.

Private Placement

Private Placement	6 Months Ended
	Jun. 30, 2021
Private Placement [Abstract]
Private Placement	Note 5 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 2,350,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $2,350,000, in a private placement (the “Private Placement”). Each Private Placement Warrant will entitle the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. The proceeds from the Private Placement Warrants was added to the proceeds from the IPO held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants are identical to the Warrants underlying the Units sold in the IPO, except that the Private Placement Warrants are non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. Further, the Sponsor has agreed not to transfer, assign, or sell the Private Placement Warrants (including the shares of Common Stock issuable upon the exercise of the Private Placement Warrants), except to certain permitted transferees, until after the consummation of the Company's initial business combination. Simultaneously with the closing of the exercise of the over-allotment option, the Company completed the private sale (the “Private Placement”) of an aggregate of 150,000 private placement warrants (the “Private Placement Warrants”) to Ignyte Sponsor LLC, a Delaware limited liability company (the “Sponsor”), at a purchase price of $1.00 per Private Placement Warrant, generating gross proceeds of $150,000.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 — Related Party Transactions Founder Shares On August 12, 2020, the Sponsor paid $25,000, or approximately $0.02 per share, to cover certain offering costs in consideration for 1,437,500 shares of Common Stock, par value $0.0001 (the “Founder Shares”). Up to 187,500 Founder Shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters' over-allotment option is exercised. On February 2, 2021, the underwriter exercised its over-allotment option in full, hence, the 187,500 Founder Shares are no longer subject to forfeiture since then. The founders' shares were placed into an escrow account maintained in New York, New York by Continental Stock Transfer & Trust Company, acting as escrow agent. Subject to certain limited exceptions, these shares will not be transferred, assigned, sold or released from escrow (subject to certain limited exceptions set forth below) (i) with respect to 50% of such shares, for a period ending on the earlier of the one-year anniversary of the date of the consummation of the initial Business Combination and the date on which the closing price of the Company's common stock equals or exceeds $12.50 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination and (ii) with respect to the remaining 50% of such shares, for a period ending on the one-year anniversary of the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to the initial Business Combination, the Company consummates a liquidation, merger, stock exchange or other similar transaction which results in all of the Company's stockholders having the right to exchange their shares of common stock for cash, securities or other property. Promissory Note — Related Party On November 20, 2020, the Company's executive officers loaned the Company $80,000 to be used for a portion of the expenses of the IPO. These loans are non-interest bearing, unsecured and are due at the earlier of June 30, 2021 or the closing of the IPO. As of February 1, 2021, the Company repaid the note in full. Due to Related Party As of June 30, 2021, the amount due to related party is $51,953 which represent the accrual of administrative service fee $51,643 from January 26, 2021 to June 30, 2021 and formation cost $310 paid by the Officer. Related Party Loans In order to meet the Company’s working capital needs following the consummation of the IPO the Sponsor, officers, directors initial stockholders or their affiliates may, but are not obligated to, loan the Company funds (“Working Capital Loans”), from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at holder’s discretion, up to $1,500,000 of the notes may be converted into warrants at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. As of June 30, 2021 and December 31, 2020, no such Working Capital Loans were outstanding. Administrative Service Fee The Company has agreed, commencing on the date of the securities of the Company are first listed on The Nasdaq Capital Market (the “Listing Date”), to pay the Sponsor $10,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company's liquidation, the Company will cease paying these monthly fees. The Company accrued $51,643 and $30,000 for the administrative service fee for the period from the Listing Date to June 30, 2021and for the three months ended June 30, 2021.

Recurring Fair Value Measuremen

Recurring Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Recurring Fair Value Measurements	Note 7 — Recurring Fair Value Measurements The following table presents information about the Company's assets and liabilities that were measured at fair value on a recurring basis as of June 30, 2021, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. 13 June 30, 2021 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Assets: U.S. Money Market held in Trust Account $ 57,504,345 $ 57,504,345 $ - $ - $ 57,504,345 $ 57,504,345 $ - $ - Liabilities: Warrant liabilities-Private Placement Warrants $ 1,875,000 $ - $ - $ 1,875,000 $ 1,875,000 $ - $ - $ 1,875,000 The following table sets forth a summary of the changes in the fair value of the warrant liabilities for the period from August 6, 2020 (Inception) through June 30, 2021: Warrant Liability Fair value as of February 1, 2021 $ 2,303,000 Issuance of private warrants in connection with over-allotment as of February 2, 2021 147,000 Change in fair value (1) (575,000) Fair value as of June 30, 2021 $ 1,875,000 (1) Represents the non-cash gain on the change in valuation of Private Warrants and is included in the change in fair value of warrant liability on the statement of operations. At June 30, 2021, the Public Warrants were determined to contain none of the features requiring liability treatment; therefore, the Public warrants were not included in the fair value reporting. The Private Warrants were valued using a Modified Black Scholes Model. The Private Warrants are considered to be a Level 3 fair value measurements due to the use of unobservable inputs. The Black Scholes Model can be modified to value SPAC Private Warrants by discounting the Acquisition Date warrant value to the Valuation Date and multiplying the present value by the probability of a future transaction occurring. Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the period from January 1, 2021 through June 30, 2021. The following table provides quantitative information regarding Level 3 fair value measurements for Private Warrants as of June 30, 2021 and February 1, 2021. June 30, 2021 February 1, 2021 Exercise price $ 11.50 $ 11.50 Share price $ 9.68 $ 10.00 Volatility 14.25 % 19.00 % Expected life 5.00 5.00 Risk-free rate 0.87 % 0.42 % Dividend yield - % - %

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 — Commitments and Contingencies Registration Rights The holders of the founders’ shares issued and outstanding on the date of the IPO, as well as the holders of the representative shares, Private Placement Warrants and any warrants the Company’s Sponsor, officers, directors or their affiliates may be issued in payment of Working Capital Loans made to the Company (and all underlying securities), will be entitled to registration rights pursuant to an agreement signed on January 27, 2021. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the founders’ shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the representative shares, Private Placement Warrants and warrants issued to the Company’s Sponsor, officers, directors or their affiliates in payment of Working Capital Loans made to the Company (or underlying securities) can elect to exercise these registration rights at any time after the Company consummates a Business Combination. Notwithstanding anything to the contrary, EarlyBirdCapital may only make a demand on one occasion and only during the five-year period beginning on the Effective Date of the registration statement of which the IPO forms a part. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a Business Combination; provided, however, that EarlyBirdCapital may participate in a “piggyback” registration only during the seven-year period beginning on the Effective Date of the registration statement of which the IPO forms a part. The Company will bear the expenses incurred in connection with the filing of any such registration statements. 14 Underwriting Agreement The underwriters have a 45-day option beginning February 1, 2021 to purchase up to an additional 750,000 units to cover over-allotments, if any, at the IPO price less the underwriting discounts. The Company issued to the underwriter (and/or its designees) (the “Representative”) 100,000 shares of common stock for $0.0001 per share (the “Representative Shares”). The Company estimated the fair value of the stock to be $2,000 based upon the price of the founder shares issued to the Sponsor. The stock were treated as underwriters’ compensation and charged directly to shareholders’ equity. The underwriter (and/or its designees) agreed (i) to waive their conversion rights (or right to participate in any tender offer) with respect to such shares in connection with the completion of our initial business combination and (ii) to waive their rights to liquidating distributions from the trust account with respect to such shares if we fail to complete our initial business combination within 21 months from the closing of this offering. On February 1, 2021, the Company paid a fixed underwriting fee of $1,000,000. On February 2, 2021, the underwriters purchased an additional 750,000 units to exercise its over-allotment option in full. The proceeds of $7,500,000 from the over-allotment was deposited in the Trust Account after deducting the underwriting discounts. Business Combination Marketing Agreement The Company has engaged underwriters as advisors in connection with its Business Combination to assist it in holding meetings with the stockholders to discuss the potential Business Combination and the target business’s attributes, introduce the Company to potential investors that are interested in purchasing the Company’s securities in connection with the potential Business Combination, assist the Company in obtaining stockholder approval for the Business Combination and assist the Company with its press releases and public filings in connection with the Business Combination. The Company will pay the Marketing Fee for such services upon the consummation of the initial Business Combination in an amount equal to, in the aggregate, 3.5% of the gross proceeds of the IPO, or $2,012,500 including the proceeds from the full exercise of the over-allotment option on February 2, 2021. Right of First Refusal If the Company determines to pursue any equity, equity-linked, debt or mezzanine financing relating to or in connection with a Business Combination or after a Business Combination, then EarlyBirdCapital shall have the right, but not the obligation, to act as book running manager, placement agent and/or arranger, as the case may be, in any and all such financing or financings and to receive at least 25% of the aggregate gross spread or fees from any and all such financings. This right of first refusal extends from the February 1, 2021 until the earlier of twelve (12) months after the consummation of an initial Business Combination or the liquidation of the Trust Account if the Company fails to consummate a Business Combination during the required time period.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholder's Equity	Note 9 — Stockholder’s Equity Preferred Stock Common Stock 15 Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with any vote held to approve the initial Business Combination, the initial stockholders, as well as all of the Company’s officers and directors, have agreed to vote their respective shares of common stock owned by them immediately prior to the IPO and any shares purchased in the IPO or following the IPO in the open market in favor of the proposed Business Combination.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed financial statements were issued.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the period for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 10-K filed by the Company with the SEC.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of unaudited condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At June 30, 2021, the assets held in the Trust Account were invested in money market funds.
Fair Value Measurements	Fair Value Measurements FASB ASC Topic 820 “Fair Value Measurements and Disclosures” (“ASC 820”) defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value of the Company’s certain assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet. The fair values of cash, prepaid assets, and accounts payable are estimated to approximate the carrying values as of December 31, 2020 due to the short maturities of such instruments. 8 The Company’s warrant liabilities are based on a valuation model utilizing management judgment and pricing inputs from observable and unobservable markets with less volume and transaction frequency than active markets. Significant deviations from these estimates and inputs could result in a material change in fair value. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. See Note 7 for additional information on assets and liabilities measured at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At June 30, 2021 and December 31, 2020, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Common Stock Subject to Possible Redemption	Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock feature certain redemption rights that is considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.
Net Income Per Common Share	Net Income Per Common Share Net income per common share is computed by dividing net income by the weighted average number of common stock outstanding for each of the periods. The calculation of diluted net income per common share does not include warrants since the inclusion of such warrants would be anti-dilutive. The Company's statement of operations includes a presentation of income per share for common stock subject to possible redemption in a manner similar to the two-class method of income per common share. Net income per common share, basic and diluted, for redeemable common stock is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of redeemable common stock outstanding since original issuance. Net income per common share, basic and diluted, for non-redeemable common stock is calculated by dividing the net income, adjusted for income attributable to redeemable common stock, by the weighted average number of non-redeemable common stock outstanding for the periods. Non-redeemable common stock includes the founder shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account. For the Three Months Ended For the Six Months Ended June 30, 2021 June 30, 2021 Common stock subject to possible redemption Numerator: net income allocable to common stock subject to possible redemption Interest income on marketable securities held in trust $ 1,862 $ 3,876 Less: interest available to be withdrawn for payment of taxes - - Net income allocable to common stock subject to possible redemption 1,862 3,876 Denominator: Weighted average redeemable common stock Redeemable common stock, basic and diluted 5,068,102 4,183,046 Basic and diluted net income per share, redeemable common stock $ - $ - Non-redeemable common stock Numerator: net income minus redeemable net earnings Net income $ 616,107 $ 269,924 Redeemable net earnings (1,862) (3,876) Non-redeemable net income 614,245 266,048 Denominator: Weighted average non-redeemable basic and diluted weighted average shares outstanding, common stock 2,219,398 2,053,694 Basic and diluted net income per share, common stock $ 0.28 $ 0.13
Offering Costs associated with the Initial Public Offering	Offering Costs associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to stockholders' equity upon the completion of the IPO. Accordingly, as of February 1, 2021, offering costs in the aggregate of $1,549,485 have been charged to stockholders' equity (consisting of $1,150,000 of underwriting discount and $399,485 of other offering costs).
Warrants Liabilities	Warrant Liabilities The Company accounts for the Public Warrants and Private Warrants (as defined in Note 4 and 5) collectively (“Warrants”), as either equity or liability-classified instruments based on an assessment of the specific terms of the Warrants and the applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the Warrants meet all of the requirements for equity classification under ASC 815, including whether the Warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and as of each subsequent quarterly period end date while the Warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Private Warrants in accordance with ASC 815-40 under which the Private Warrants do not meet the criteria for equity classification and must be recorded as liabilities. The fair value of the Private Warrants has been estimated using the Monte Carlo simulation model. See Note 7 for further discussion of the pertinent terms of the Warrants used to determine the value of the Private Warrants and Representative’s Warrants. The Company evaluated the Public Warrants in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity” and concluded that they met the criteria for equity classification and are required to be recorded as part a component of additional paid-in capital at the time of issuance.
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. 10 ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Risks and Uncertainties	Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the ”COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s financial position will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s financial position may be materially adversely affected. Additionally, the Company’s ability to complete an initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an initial Business Combination in a timely manner. The Company’s ability to consummate an initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Recent Accounting Standards	Recent Accounting Standards Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statement.

Revision of Previously Issued_2

Revision of Previously Issued Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2021
Revision Of Previously Issued Financial Statements
Schedule of effect of Restatement on Each Balance Sheet Line Item	The following tables summarize the effect of the restatement on each balance sheet line item as of the date: As Previously Reported Adjustment As Revised Balance Sheet at February 1, 2021 Warrant Liabilities $ - $ 2,303,000 $ 2,303,000 Total Liabilities 426,200 2,303,000 2,729,200 Common stock subject to possible redemption 45,973,118 (2,303,000) 43,670,118 Common stock 194 23 217 Additional paid-in capital 5,004,203 (23) 5,004,180 Accumulated deficit $ (4,396) $ - $ (4,396) Total Stockholders' Equity 5,000,001 - 5,000,001 Number of shares subject to redemption 4,597,312 (230,300) 4,367,012

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Schedule of Net Income Per Common Share	For the Three Months Ended For the Six Months Ended June 30, 2021 June 30, 2021 Common stock subject to possible redemption Numerator: net income allocable to common stock subject to possible redemption Interest income on marketable securities held in trust $ 1,862 $ 3,876 Less: interest available to be withdrawn for payment of taxes - - Net income allocable to common stock subject to possible redemption 1,862 3,876 Denominator: Weighted average redeemable common stock Redeemable common stock, basic and diluted 5,068,102 4,183,046 Basic and diluted net income per share, redeemable common stock $ - $ - Non-redeemable common stock Numerator: net income minus redeemable net earnings Net income $ 616,107 $ 269,924 Redeemable net earnings (1,862) (3,876) Non-redeemable net income 614,245 266,048 Denominator: Weighted average non-redeemable basic and diluted weighted average shares outstanding, common stock 2,219,398 2,053,694 Basic and diluted net income per share, common stock $ 0.28 $ 0.13

Recurring Fair Value Measurem_2

Recurring Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value on a Recurring Basis	The following table presents information about the Company's assets and liabilities that were measured at fair value on a recurring basis as of June 30, 2021, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. 13 June 30, 2021 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Other Unobservable Inputs (Level 3) Assets: U.S. Money Market held in Trust Account $ 57,504,345 $ 57,504,345 $ - $ - $ 57,504,345 $ 57,504,345 $ - $ - Liabilities: Warrant liabilities-Private Placement Warrants $ 1,875,000 $ - $ - $ 1,875,000 $ 1,875,000 $ - $ - $ 1,875,000
Schedule of Fair Value of Warrants liabilities	The following table sets forth a summary of the changes in the fair value of the warrant liabilities for the period from August 6, 2020 (Inception) through June 30, 2021: Warrant Liability Fair value as of February 1, 2021 $ 2,303,000 Issuance of private warrants in connection with over-allotment as of February 2, 2021 147,000 Change in fair value (1) (575,000) Fair value as of June 30, 2021 $ 1,875,000 (1) Represents the non-cash gain on the change in valuation of Private Warrants and is included in the change in fair value of warrant liability on the statement of operations.
Schedule of Fair Value Measurements for Private Warrants	The following table provides quantitative information regarding Level 3 fair value measurements for Private Warrants as of June 30, 2021 and February 1, 2021. June 30, 2021 February 1, 2021 Exercise price $ 11.50 $ 11.50 Share price $ 9.68 $ 10.00 Volatility 14.25 % 19.00 % Expected life 5.00 5.00 Risk-free rate 0.87 % 0.42 % Dividend yield - % - %

Organization and Business Ope_2

Organization and Business Operations (Details) - USD ($)	Feb. 02, 2021	Feb. 01, 2021	Mar. 31, 2021	Jun. 30, 2021
Gross proceeds from Initial public offering	$ 2,012,500			$ 56,350,000
Proceeds from private placement				2,500,000
Amount held in trust accounts		$ 7,500,000
Payment of underwriting discount		150,000	$ 1,150,000
Transaction costs		1,549,485
Underwriting fees		1,000,000
Cash held in outside trust account		975,465
Other offering costs		$ 399,485	$ 399,485	399,485
Net tangible assets				5,000,001
Dissolution expenses				50,000
Amount in operating bank account				550,470
Working capital				667,784
Offering costs				25,000
Unsecured promissory note				$ 80,000
Public Shares [Member]
Company's obligation to redeemed, percentage				100.00%
IPO [Member]
Initial public offering shares		5,000,000		5,000,000
Share price per units		$ 10		$ 10
Gross proceeds from Initial public offering		$ 50,000,000
Share price				$ 11.50
Private Placement Warrants [Member]
Number of shares issue	150,000	2,350,000
Proceeds from private placement	$ 150,000	$ 2,350,000
Share price	$ 1	$ 1
Underwriters [Member]
Share price per units	$ 10
Number of shares issue	750,000
Gross proceeds from underwriters	$ 7,500,000

Revision of Previously Issued_3

Revision of Previously Issued Financial Statements (Narrative) (Details) - shares	Feb. 02, 2021	Feb. 01, 2021
Public Warrants [Member]
Number of warrants		2,875,000
Private Placement Warrants [Member]
Number of warrants	2,500,000

Revision of Previously Issued_4

Revision of Previously Issued Financial Statements (Schedule of effect of Restatement on Each Balance Sheet) (Details) - USD ($)	Jun. 30, 2021	Mar. 31, 2021	Feb. 01, 2021	Dec. 31, 2020
Warrant Liabilities			$ 2,303,000
Total Liabilities	$ 1,939,609		2,729,200	$ 80,310
Common stock subject to possible redemption	51,297,120		43,670,118
Common stock	216		217	154
Additional paid-in capital	4,730,179		5,004,180	26,846
Accumulated deficit	269,614		(4,396)	(310)
Total Stockholders' Equity	$ 5,000,009	$ 5,000,002	$ 5,000,001	$ 26,690
Number of shares subject to redemption	5,129,712		4,367,012	0
Previously Reported [Member]
Warrant Liabilities
Total Liabilities			426,200
Common stock subject to possible redemption			45,973,118
Common stock			194
Additional paid-in capital			5,004,203
Accumulated deficit			(4,396)
Total Stockholders' Equity			$ 5,000,001
Number of shares subject to redemption			4,597,312
Adjustment [Member]
Warrant Liabilities			$ 2,303,000
Total Liabilities			2,303,000
Common stock subject to possible redemption			(2,303,000)
Common stock			23
Additional paid-in capital			(23)
Accumulated deficit
Total Stockholders' Equity
Number of shares subject to redemption			(230,300)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	Feb. 01, 2021	Mar. 31, 2021	Jun. 30, 2021
Schedule of basic and diluted net loss per ordinary share [Abstract]
Federal Depository Insurance Coverage			$ 250,000
Offering costs	$ 1,549,485
Other offering costs	$ 399,485	$ 399,485	$ 399,485

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Schedule of Net Loss Per Common Share) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021
Numerator: net income allocable to common stock subject to possible redemption
Interest income on marketable securities held in trust	$ 1,862		$ 3,876
Less: interest available to be withdrawn for payment of taxes
Net income allocable to common stock subject to possible redemption	1,862		3,876
Denominator: Weighted average redeemable common stock
Redeemable common stock, basic and diluted	$ 5,068,102		$ 4,183,046
Basic and diluted net income per share, redeemable common stock
Non-redeemable common stock: Numerator: net income minus redeemable net earnings
Net income	$ 616,107	$ (346,183)	$ 269,924
Redeemable net earnings	(1,862)		(3,876)
Non-redeemable net income	$ 614,245		$ 266,048
Denominator: Weighted average non-redeemable basic and diluted weighted average shares outstanding, common stock	2,219,398		2,053,694
Basic and diluted net income per share, common stock	$ 0.28		$ 0.13

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)	Feb. 02, 2021	Feb. 01, 2021	Mar. 31, 2021	Jun. 30, 2021
Gross proceeds from initial public offering	$ 2,012,500			$ 56,350,000
Underwriting fees		$ 150,000	$ 1,150,000
Warrant redemption price per share				$ 0.01
Last sale price of Common Stock				18
Minimum [Member]
Initial public offering per share (in Dollars per share)				$ 9.20
IPO [Member]
Initial public offering shares		5,000,000		5,000,000
Initial public offering per share (in Dollars)		$ 10		$ 10
Initial public offering per share (in Dollars per share)				$ 11.50
Gross proceeds from initial public offering		$ 50,000,000
Over-Allotment Option [Member]
Initial public offering shares				750,000
Gross proceeds from initial public offering	$ 7,500,000			$ 7,500,000
Underwriting fees				$ 150,000

Private Placement (Details)

Private Placement (Details)	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Aggregate purchase price, amount	$ 2,500,000
Private Placement [Member]
Purchase price | shares	2,350,000
Stock price | $ / shares	$ 1
Aggregate purchase price, amount	$ 2,350,000
Private placement, description	Each Private Placement Warrant will entitle the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment.
Private Placement [Member] | Ignyte Sponsor LLC [Member]
Stock price | $ / shares	$ 1
Sale of private placement warrants | shares	150,000
Proceeds from sale of warrants	$ 150,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Feb. 02, 2021	Aug. 12, 2020	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Feb. 01, 2021	Dec. 31, 2020	Nov. 20, 2020
Related Party Transaction [Line Items]
Purchase price of founder shares					$ 57,500,000
Par value of common shares issued				$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Amount due to related party				$ 51,953		$ 51,953	$ 51,953
Converted amount							$ 1,500,000
Sale of price per share (in Dollars per share)				$ 1		$ 1	$ 1
Office space, utilities and secretarial support [Member]
Related Party Transaction [Line Items]
Per month amount							$ 10,000
Over-Allotment Option [Member]
Related Party Transaction [Line Items]
Forfeiture of founder shares (in Shares)		187,500
Founder Shares [Member]
Related Party Transaction [Line Items]
Shares not subject to forfeiture	187,500
IPO [Member]
Related Party Transaction [Line Items]
Share price (in Dollars per share)				$ 10		$ 10	$ 10	$ 10
IPO [Member] | Executive Officers [Member]
Related Party Transaction [Line Items]
Promissory note, outstanding										$ 80,000
Founder Shares [Member]
Related Party Transaction [Line Items]
Purchase price of founder shares		$ 25,000
Issuance of common stock to founder, shares (in Shares)		1,437,500
Par value of common shares issued		$ 0.0001
Founder shares, description							Subject to certain limited exceptions, these shares will not be transferred, assigned, sold or released from escrow (subject to certain limited exceptions set forth below) (i) with respect to 50% of such shares, for a period ending on the earlier of the one-year anniversary of the date of the consummation of the initial Business Combination and the date on which the closing price of the Company's common stock equals or exceeds $12.50 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination and (ii) with respect to the remaining 50% of such shares, for a period ending on the one-year anniversary of the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to the initial Business Combination, the Company consummates a liquidation, merger, stock exchange or other similar transaction which results in all of the Company's stockholders having the right to exchange their shares of common stock for cash, securities or other property.
Share price (in Dollars per share)		$ 0.02
Accrual of Administrative Service Fees [Member]
Related Party Transaction [Line Items]
Related party transaction amount				$ 30,000		$ 51,643	$ 51,643
Formation cost [Member] | Officer [Member]
Related Party Transaction [Line Items]
Related party cost			$ 310

Recurring Fair Value Measurem_3

Recurring Fair Value Measurements (Schedule of Fair Value on a Recurring Basis) (Details)	Jun. 30, 2021USD ($)
Assets:
U.S. Money Market held in Trust Account	$ 57,504,345
Assets:	57,504,345
Liabilities:
Warrant liabilities-Private Placement Warrants	1,875,000
Liabilities:	1,875,000
Quoted Prices In Active Markets (Level 1) [Member]
Assets:
U.S. Money Market held in Trust Account	57,504,345
Assets:	57,504,345
Liabilities:
Warrant liabilities-Private Placement Warrants
Liabilities:
Significant Other Observable Inputs (Level 2) [Member]
Assets:
U.S. Money Market held in Trust Account
Assets:
Liabilities:
Warrant liabilities-Private Placement Warrants
Liabilities:
Significant Other Observable Inputs (Level 3) [Member]
Assets:
U.S. Money Market held in Trust Account
Assets:
Liabilities:
Warrant liabilities-Private Placement Warrants	1,875,000
Liabilities:	$ 1,875,000

Recurring Fair Value Measurem_4

Recurring Fair Value Measurements (Schedule of Fair Value of Warrants Liabilities) (Details) - USD ($)		6 Months Ended	11 Months Ended
		Jun. 30, 2021	Jun. 30, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value		$ (575,000)
Warrant Liability [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value as of February 1, 2021			$ 2,303,000
Issuance of private warrants in connection with over-allotment as of February 2, 2021			147,000
Change in fair value	[1]		(575,000)
Fair value as of June 30, 2021		$ 1,875,000	$ 1,875,000
[1]	Represents the non-cash gain on the change in valuation of Private Warrants and is included in the change in fair value of warrant liability on the statement of operations.

Recurring Fair Value Measurem_5

Recurring Fair Value Measurements (Schedule of Fair value Measurements for Private Warrants) (Details) - Private Warrants [Member] - $ / shares	Feb. 01, 2021	Jun. 30, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 11.50	$ 11.50
Share price	$ 10	$ 9.68
Volatility	19.00%	14.25%
Expected life	5 years	5 years
Risk-free rate	0.42%	0.87%
Dividend yield

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Feb. 02, 2021	Feb. 01, 2021	Mar. 31, 2021	Jun. 30, 2021
Loss Contingencies [Line Items]
Gross proceeds from initial public offering	$ 2,012,500			$ 56,350,000
Representative Shares issued, value			$ 57,500,000
Underwriting fee		$ 1,000,000
Gross proceeds percentange	3.50%
Percentage of aggregate gross spread or fees from any and all such financings		25.00%
Over-Allotment Option [Member]
Loss Contingencies [Line Items]
Gross proceeds from initial public offering	$ 7,500,000			$ 7,500,000
Aggregate purchase units (in Shares)	750,000	750,000
Over-Allotment Option [Member] | Underwriter (and/or its designees) [Member]
Loss Contingencies [Line Items]
Number of shares issue		100,000
Representative Shares issued, value		$ 2,000
Representative Shares issued price per share		$ 0.0001

Stockholder's Equity (Details)

Stockholder's Equity (Details) - USD ($)	Aug. 12, 2020	Mar. 31, 2021	Jun. 30, 2021	Feb. 03, 2021	Dec. 31, 2020	Aug. 30, 2020
Class of Stock [Line Items]
Preference shares, shares authorized			1,000,000		1,000,000
Preferred stock, par value (in Dollars per share)			$ 0.0001		$ 0.0001
Preference shares, shares issued			0		0
Preference shares, shares outstanding			0		0
Common stock, shares authorized			50,000,000		50,000,000
Common stock, par value (in Dollars per share)			$ 0.0001		$ 0.0001
Common stock, shares issued			2,157,788		2,157,788
Common stock, shares outstanding			0		0
Common stock, shares forfeiture			187,500
Percentage of shares owned by stockholders in issued and outstanding common stock after IPO			20.00%
Number of Founder Shares are no longer subject to forfeiture since IPO				187,500
Purchase price of founder shares		$ 57,500,000
Designees of EarlyBirdCapital [Member]
Class of Stock [Line Items]
Common stock, par value (in Dollars per share)						$ 0.0001
Common stock, shares issued						100,000
Founder Shares [Member]
Class of Stock [Line Items]
Common stock, par value (in Dollars per share)	$ 0.0001
Purchase price of founder shares	$ 25,000
Share price (in Dollars per share)	$ 0.02
Issuance of common stock to founder, shares (in Shares)	1,437,500